Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating restated by equities research analysts at Cowen and Company in a report released on Tuesday.
The analysts wrote, “Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of.””
A number of other analysts have also recently commented on MYOV. Robert W. Baird restated a “buy” rating and issued a $20.00 price objective on shares of Myovant Sciences in a research report on Friday. Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. JMP Securities restated an “outperform” rating and issued a $25.00 price objective (up from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Finally, Evercore ISI initiated coverage on Myovant Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.00.
Shares of Myovant Sciences (NASDAQ MYOV) traded down $0.69 during trading hours on Tuesday, reaching $13.43. The company’s stock had a trading volume of 80,410 shares, compared to its average volume of 35,778. Myovant Sciences has a one year low of $9.92 and a one year high of $18.85.
Several institutional investors have recently bought and sold shares of the company. OxFORD Asset Management LLP increased its position in shares of Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after buying an additional 3,971 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after buying an additional 6,330 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after buying an additional 12,700 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Myovant Sciences in the second quarter valued at approximately $165,000. Finally, JPMorgan Chase & Co. increased its position in shares of Myovant Sciences by 18.4% during the third quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock worth $1,382,000 after purchasing an additional 14,203 shares in the last quarter.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.